HDL3-C is a Marker of Coronary Artery Disease Severity and Inflammation in Patients on Statin Therapy
Highlights
- • Limited data are available determining the role of HDL-C sub-particles HDL2-C and HDL3-C for assessing CAD severity in patients on statin therapy.
- • This is the first study to propose HDL3-C, as a novel biomarker for predicting angiographically defined severe CAD.
- • Low HDL3-C and high Lp(a)-C levels have a significant association with Ox-LDL, a marker of inflammation.
- • In patients on statin therapy, HDL3-C and Lp(a)-C improve prediction of the presence of severe CAD compared to a traditional lipid panel.
Abstract
Introduction
Low high-density lipoprotein (HDL-C) and inflammation are risk factors for coronary artery disease (CAD). However, limited data are available determining the role of HDL-C sub-particles HDL2-C and HDL3-C for assessing CAD severity in patients on statin therapy.